文献速递临床试验与 GCP流行病学与生物统计

早期目标导向治疗对脓毒性休克的作用——患者水平Meta分析

Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis.
PubMed 文献 · N Engl J Med · 2017-03-21

该研究前瞻性设计,汇总ProCESS、ARISE和ProMISe三项多中心试验的个体患者数据,比较早期目标导向治疗(EGDT)与常规治疗的疗效。共纳入7国138家医院3723例患者,EGDT组90天死亡率24.9%与常规组25.4%相似(调整OR 0.97,95%CI 0.82-1.14,P=0.68),但EGDT组ICU使用和心血管支持时间更长、平均费用更高,亚组分析未发现获益人群。

要点

  • EGDT组90天死亡率24.9%与常规组25.4%相似,调整OR 0.97(95%CI 0.82-1.14,P=0.68)。
  • EGDT组ICU使用时间5.3±7.1天 vs 常规组4.9±7.0天(P=0.04),心血管支持时间1.9±3.7天 vs 1.6±2.9天(P=0.01)。
  • 亚组分析未显示休克更重患者或升压药/液体使用倾向较低医院中EGDT有获益。

核心结论

  • 在个体患者数据Meta分析中,EGDT未比常规治疗带来更好结局,且在广泛患者和医院特征中与更高住院费用相关。

研究设计与样本

  • 前瞻性设计的个体患者数据Meta分析,汇总ProCESS、ARISE和ProMISe三项多中心试验,排除ProCESS试验中方案规定的标准治疗组。
  • 共纳入7个国家138家医院的3723例患者,主要结局为90天死亡率,次要结局包括1年生存、器官支持和住院费用。

主要发现

  • 90天死亡率EGDT组462/1852例(24.9%)vs 常规治疗组475/1871例(25.4%),调整OR 0.97(95%CI 0.82-1.14,P=0.68)。
  • EGDT组ICU使用时间5.3±7.1天 vs 常规组4.9±7.0天(P=0.04),心血管支持时间1.9±3.7天 vs 1.6±2.9天(P=0.01)。
  • 其他结局无显著差异,但EGDT组平均费用更高。
  • 亚组分析显示,对于休克更重患者(更高血清乳酸水平、低血压合并高乳酸血症或更高预测死亡风险)或常规复苏中升压药/液体使用倾向较低的医院,EGDT均无获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After a single-center trial and observational studies suggesting that early, goal-directed therapy (EGDT) reduced mortality from septic shock, three multicenter trials (ProCESS, ARISE, and ProMISe) showed no benefit. This meta-analysis of individual patient data from the three recent trials was designed prospectively to improve statistical power and explore heterogeneity of treatment effect of EGDT. METHODS: We harmonized entry criteria, intervention protocols, outcomes, resource-use measures, and data collection across the trials and specified all analyses before unblinding. After completion of the trials, we pooled data, excluding the protocol-based standard-therapy group from the ProCESS trial, and resolved residual differences. The primary outcome was 90-day mortality. Secondary outcomes included 1-year survival, organ support, and hospitalization costs. We tested for treatment-by-subgroup interactions for 16 patient characteristics and 6 care-delivery characteristics. RESULTS: We studied 3723 patients at 138 hospitals in seven countries. Mortality at 90 days was similar for EGDT (462 of 1852 patients [24.9%]) and usual care (475 of 1871 patients [25.4%]); the adjusted odds ratio was 0.97 (95% confidence interval, 0.82 to 1.14; P=0.68). EGDT was associated with greater mean (±SD) use of intensive care (5.3±7.1 vs. 4.9±7.0 days, P=0.04) and cardiovascular support (1.9±3.7 vs. 1.6±2.9 days, P=0.01) than was usual care; other outcomes did not differ significantly, although average costs were higher with EGDT. Subgroup analyses showed no benefit from EGDT for patients with worse shock (higher serum lactate level, combined hypotension and hyperlactatemia, or higher predicted risk of death) or for hospitals with a lower propensity to use vasopressors or fluids during usual resuscitation. CONCLUSIONS: In this meta-analysis of individual patient data, EGDT did not result in better outcomes than usual care and was associated with higher hospitalization costs across a broad range of patient and hospital characteristics. (Funded by the National Institute of General Medical Sciences and others; PRISM ClinicalTrials.gov number, NCT02030158 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Rowan KM, Angus DC, Bailey M, et al. Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis. N Engl J Med. 2017. PMID: 28320242. doi:10.1056/NEJMoa1701380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。